Gilead Gets Injunction Against Abbott And India’s Lyka On Amphotericin Brands
This article was originally published in PharmAsia News
Executive Summary
What’s in a name? Everything, Gilead would say going by the latest injunction it obtained against Abbott and Indian drug maker Lyka. Gilead says the two drug companies were marketing confusingly similar generic brands of its anti-fungal amphotericin. But is there a bigger angle to the story?